Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis

Chandana B Herath; Fiona Jane Warner; John S Lubel; Rachel G Dean; Zhiyuan Jia; Rebecca Ann Lew; Alexander Ian Smith; Louise M Burrell; Peter W Angus

Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis

Chandana B Herath, Fiona Jane Warner, John S Lubel, Rachel G Dean, Zhiyuan Jia, Rebecca Ann Lew, Alexander Ian Smith, Louise M Burrell, Peter W Angus

Biochemistry & Molecular Biology

Research output: Contribution to journal › Article › Research › peer-review

118 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Angiotensin-converting enzyme 2 (ACE2), its product, angiotensin-(1-7) and its receptor, Mas, may moderate the adverse effects of angiotensin II in liver disease. We examined the expression of these novel components of the renin angiotensin system (RAS) and the production and vasoactive effects of angiotensin-(1-7) in the bile duct ligated (BDL) rat. METHODS: BDL or sham-operated rats were sacrificed at 1, 2, 3 and 4 weeks. Tissue and blood were collected for gene expression, enzyme activity and peptide measurements. In situ perfused livers were used to assess angiotensin peptide production and their effects on portal resistance. RESULTS: Hepatic ACE2 gene and activity (P

Original language	English
Pages (from-to)	387 - 395
Number of pages	9
Journal	Journal of Hepatology
Volume	47
Issue number	3
Publication status	Published - 2007

Cite this

@article{394cc0b14d04429facf465596c12ce01,

title = "Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis",

abstract = "BACKGROUND/AIMS: Angiotensin-converting enzyme 2 (ACE2), its product, angiotensin-(1-7) and its receptor, Mas, may moderate the adverse effects of angiotensin II in liver disease. We examined the expression of these novel components of the renin angiotensin system (RAS) and the production and vasoactive effects of angiotensin-(1-7) in the bile duct ligated (BDL) rat. METHODS: BDL or sham-operated rats were sacrificed at 1, 2, 3 and 4 weeks. Tissue and blood were collected for gene expression, enzyme activity and peptide measurements. In situ perfused livers were used to assess angiotensin peptide production and their effects on portal resistance. RESULTS: Hepatic ACE2 gene and activity (P",

author = "Herath, {Chandana B} and Warner, {Fiona Jane} and Lubel, {John S} and Dean, {Rachel G} and Zhiyuan Jia and Lew, {Rebecca Ann} and Smith, {Alexander Ian} and Burrell, {Louise M} and Angus, {Peter W}",

year = "2007",

language = "English",

volume = "47",

pages = "387 -- 395",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier BV",

number = "3",

}

Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. / Herath, Chandana B; Warner, Fiona Jane; Lubel, John S; Dean, Rachel G; Jia, Zhiyuan; Lew, Rebecca Ann; Smith, Alexander Ian; Burrell, Louise M; Angus, Peter W.

In: Journal of Hepatology, Vol. 47, No. 3, 2007, p. 387 - 395.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis

AU - Herath, Chandana B

AU - Warner, Fiona Jane

AU - Lubel, John S

AU - Dean, Rachel G

AU - Jia, Zhiyuan

AU - Lew, Rebecca Ann

AU - Smith, Alexander Ian

AU - Burrell, Louise M

AU - Angus, Peter W

PY - 2007

Y1 - 2007

N2 - BACKGROUND/AIMS: Angiotensin-converting enzyme 2 (ACE2), its product, angiotensin-(1-7) and its receptor, Mas, may moderate the adverse effects of angiotensin II in liver disease. We examined the expression of these novel components of the renin angiotensin system (RAS) and the production and vasoactive effects of angiotensin-(1-7) in the bile duct ligated (BDL) rat. METHODS: BDL or sham-operated rats were sacrificed at 1, 2, 3 and 4 weeks. Tissue and blood were collected for gene expression, enzyme activity and peptide measurements. In situ perfused livers were used to assess angiotensin peptide production and their effects on portal resistance. RESULTS: Hepatic ACE2 gene and activity (P

AB - BACKGROUND/AIMS: Angiotensin-converting enzyme 2 (ACE2), its product, angiotensin-(1-7) and its receptor, Mas, may moderate the adverse effects of angiotensin II in liver disease. We examined the expression of these novel components of the renin angiotensin system (RAS) and the production and vasoactive effects of angiotensin-(1-7) in the bile duct ligated (BDL) rat. METHODS: BDL or sham-operated rats were sacrificed at 1, 2, 3 and 4 weeks. Tissue and blood were collected for gene expression, enzyme activity and peptide measurements. In situ perfused livers were used to assess angiotensin peptide production and their effects on portal resistance. RESULTS: Hepatic ACE2 gene and activity (P

UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17532087

M3 - Article

VL - 47

SP - 387

EP - 395

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -

Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis

Abstract

Other files and links

Cite this